Developer docs
API playgroundTry for free, no card

Search company profiles

Ascletis

Full company profile

uuid00035c6

Namestring
Ascletis
Legal namestring
Ascletis Pharma Inc.
Websiteurl
ascletis.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Ascletis Pharma Inc. is a fully integrated, publicly traded (HKEX: 1672.HK) biotechnology company headquartered in Hangzhou, China, founded in 2013 by Dr. Jinzi Jason Wu. The company develops and commercializes small-molecule and peptide therapeutics with its primary current focus on metabolic diseases — particularly obesity — while retaining a legacy footprint in viral hepatitis (HCV/HBV). The technology base rests on three proprietary platforms: Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), the Ultra-Long-Acting Platform (ULAP) for subcutaneous depot formulations, and Peptide Oral Transport ENhancement Technology (POTENT), which the company claims delivers 3–5% oral bioavailability for peptides versus sub-1% with conventional SNAC formulations. Its lead clinical asset is ASC30, a small-molecule GLP-1R agonist designed for once-daily oral or once-monthly-to-quarterly subcutaneous dosing, supported by a portfolio of differentiated obesity candidates (ASC35 dual GLP-1R/GIPR, ASC36 amylin, ASC37 triple GLP-1R/GIPR/GCGR, ASC39 oral amylin, and an ASC30/ASC39 FDC).

The company's commercial revenue comes from a narrow hepatitis product set: Ganovo (Danoprevir), the first domestically developed DAA in China; Ravidasvir (ASC16); and exclusive mainland China sales/marketing rights for Roche's Pegasys for HBV/HCV, distributed via a strategic partnership with CR Pharmaceutical Commercial Group covering all 31 Chinese provinces. Pricing is mediated through provincial medical insurance reimbursement programs (Tianjin, Chengdu, Shaoxing, Zhejiang). Reported revenue is small (H1 prior-year revenue of approximately CNY 104M more than doubled year-over-year) and the company is unprofitable with annual losses of approximately CNY 359.88M, so equity value is driven primarily by pipeline optionality rather than current product cash flow. Additional late-stage assets include denifanstat (ASC40), a first-in-class oral FASN inhibitor for moderate-to-severe acne with NDA accepted by China's NMPA, and ASC22 (Envafolimab) for HBV functional cure.

Short descriptiontext

Ascletis Pharma Inc. is a Hong Kong-listed biotechnology company (1672.HK) developing and commercializing differentiated small-molecule and peptide therapeutics — anchored by obesity lead ASC30 — using proprietary AI-assisted discovery, ultra-long-acting depot, and oral peptide delivery platforms, with legacy hepatitis products distributed across China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHangzhou, China
HQ citystring
Hangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metabolic disease therapeutics, GLP-1 receptor agonists, antiviral hepatitis drugs, small molecule drug discovery, peptide therapeutics platform
Industry3 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Ganovo (Danoprevir) Sales
TypeOne Time License
Description

Commercial sales of Ganovo, the first domestically developed DAA for hepatitis C in China, with reimbursement access through multiple provincial medical insurance programs (Tianjin, Chengdu, Shaoxing, Zhejiang).

ascletis.com
2Pegasys Distribution Partnership with Roche
TypeLicensing Royalties
Description

Ascletis holds exclusive sales and marketing promotion rights for Pegasys (peginterferon alfa-2a) in mainland China for HBV and HCV, leveraging Roche's established brand and Ascletis's hepatitis focus.

ascletis.com
3Denifanstat (ASC40) - Acne
TypeOne Time License
Description

First-in-class oral FASN inhibitor for moderate-to-severe acne vulgaris. NDA accepted by China's NMPA. Awaiting commercial launch.

finance.yahoo.com
4Licensing Royalties and Milestone Payments - Sagimet Partnership
TypeLicensing Royalties
Description

Ascletis holds exclusive license to develop and commercialize Sagimet's FASN inhibitor denifanstat/ASC40 in Greater China, with milestone payments and tiered royalties from mid-teens to ~20% on net sales.

stocktitan.net
5Pipeline Drug Development - Clinical Milestones
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biopharma with multiple pipeline candidates (ASC30, ASC35, ASC36, ASC37, ASC39) advancing through clinical trials. Revenue generation contingent on successful clinical and regulatory outcomes.

en.prnasia.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Ganovo
Description

First direct-acting anti-viral agent for hepatitis C developed domestically in China (Danoprevir)

ascletis.com
+7 more records
Core offering1 text field

Ascletis is a fully integrated biotechnology company that discovers, develops, and commercializes therapeutics for metabolic diseases (primarily obesity and diabetes), viral hepatitis, NASH, and acne. The company uses three proprietary platforms—AI-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT)—to develop small molecule and peptide drug candidates such as ASC30 (lead GLP-1R agonist), ASC35, ASC36, ASC37, ASC39, Ganovo (HCV DAA), Ravidasvir, Pegasys, and denifanstat.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • ASC30 subcutaneous depot: 7.5% placebo-adjusted mean weight loss at Week 16 in 65 obese participants after 3 monthly doses (Phase II)
+8 more records
Product overview1 text field

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing and commercializing therapeutics for metabolic diseases. The company has developed multiple drug candidates in-house using its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). The portfolio includes ASC30 as the lead program (small molecule GLP-1R agonist with oral daily and subcutaneous monthly/quarterly dosing), supported by peptide agonists ASC35, ASC36, ASC37, and fixed-dose combinations. Commercial products include Ganovo and Ravidasvir for hepatitis C, Pegasys for HBV/HCV partnered with Roche, and denifanstat (ASC40) approaching launch for acne.

Product and service13 records
1ASC30
CategoryObesity Therapeutics
2ASC35
CategoryObesity Therapeutics
3ASC36
CategoryObesity Therapeutics
4ASC37
CategoryObesity Therapeutics
5ASC39
CategoryObesity Therapeutics
6ASC30_39 FDC
CategoryObesity Therapeutics
7Denifanstat (ASC40)
CategoryDermatology Therapeutics
8Ganovo (Danoprevir/ASC08)
CategoryHepatitis C Antiviral
9Ravidasvir (ASC16)
CategoryHepatitis C Antiviral
10Pegasys (Peginterferon alfa-2a)
CategoryHepatitis B/C Antiviral
11ASC22 (Envafolimab)
CategoryHepatitis B Functional Cure
12ASC47
CategoryObesity Therapeutics
13ASC50
CategoryImmune Disease Therapeutics
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

In November 2018, Ascletis and Roche entered an exclusive partnership granting Ascletis sales and marketing promotion rights for Pegasys (peginterferon alfa-2a) in mainland China for hepatitis B and C. Roche maintains manufacturing and supply. This builds on Ascletis' prior successful Ganovo partnership with Roche (which licensed danoprevir/ASC08 to Ascletis in 2013).

2Suzhou Alphamab Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

In January 2019, Ascletis entered an exclusive licensing and strategic collaboration with Alphamab for anti-PD-L1 KN035 (ASC22) to treat hepatitis B and other viral diseases in Greater China. Alphamab manufactures ASC22 for clinical trials and commercialization. In November 2021, the partnership was expanded into a worldwide license agreement.

ascletis.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

In February 2019, Ascletis and Sagimet entered an exclusive license agreement for FASN inhibitor TVB-2640 (denifanstat, ASC40) in Greater China. Ascletis led the $18M Series E financing and contributed to a further $7M tranche. Sagimet is developing denifanstat for NASH, acne, and other indications globally. Ascletis' NDA for denifanstat for acne has been accepted by China's NMPA. Sagimet is planning US Phase 3 acne trial in H2 2026.

4CR Pharmaceutical Commercial Group Co., Ltd. (China Resources)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

In June 2018, Ascletis and CR Pharmaceutical Commercial Group (a subsidiary of China Resources Pharmaceutical Group Limited, HK: 3320) signed a strategic cooperation agreement for distribution networks and end-user services for Ganovo. CR Pharma is China's second-largest pharmaceutical distributor, directly serving hospitals and medical institutions across all 31 provinces.

ascletis.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

In August 2017, Ascletis licensed exclusive rights from Medivir to develop, manufacture and commercialize MIV-802 (ASC21), a nucleotide polymerase inhibitor for hepatitis C, in Greater China. Medivir received upfront and milestone payments plus tiered royalties.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Innovent Biologics is a leading Chinese biopharmaceutical company listed on HKEX with a focus on innovative medicines for oncology, metabolic diseases, and autoimmune conditions. Comparable as a Hong Kong-listed Chinese biotech with similar scale, R&D intensity, and pipeline breadth including metabolic disease programs (e.g., mazdutide).

2Hansoh Pharmaceutical
TypeDirect peer
Description

Hansoh Pharmaceutical is one of China's largest innovative drug developers, listed on HKEX, with established presence in oncology, metabolic, and CNS therapeutic areas. Comparable as a Chinese pharmaceutical innovator with similar R&D-driven business model and HKEX listing.

TypeBroad incumbent
Description

Eli Lilly is the global leader in the GLP-1 obesity market with Mounjaro (tirzepatide) and Zepbound. Ascletis directly references Eli Lilly's orforglipron as a Phase II comparator for ASC30, making it the most clinically relevant incumbent in Ascletis's core competitive set.

TypeBroad incumbent
Description

Novo Nordisk is the dominant incumbent in diabetes and obesity with Ozempic/Wegovy (semaglutide), including the oral semaglutide formulation. Ascletis's ASC30 oral GLP-1 program directly competes for the same prescriber and patient pool.

TypeEmerging player
Description

Structure Therapeutics is a clinical-stage biotech developing oral small molecule GLP-1R agonists (GSBR-1290) for obesity. Directly comparable as a peer company pursuing oral small molecule GLP-1 with similar mechanism to ASC30, but focused exclusively on that asset.

TypeDirect peer
Description

Sagimet Biosciences (NASDAQ: SGMT) is the originator and global developer of denifanstat (ASC40), the FASN inhibitor licensed to Ascletis for Greater China. Directly comparable as a co-developer of Ascletis's near-term commercial asset and as a metabolic disease-focused clinical-stage biotech.

TypeEmerging player
Description

Viking Therapeutics is a US clinical-stage biotech developing VK2735 (dual GLP-1/GIP agonist) and oral formulation programs. Directly comparable to Ascletis's ASC35/ASC37 dual and triple agonists in the obesity space, with similar mechanism of action.

TypeEmerging player
Description

Terns Pharmaceuticals is a US-listed clinical-stage biotech developing oral GLP-1R agonist (TERN-601) and other metabolic disease assets. Comparable as a peer pursuing oral small molecule GLP-1 with similar mechanism to ASC30.

TypeDirect peer
Description

Akeso Inc. is a Hong Kong-listed Chinese biotech developing novel bispecific antibodies and other biologics for cancer and autoimmune diseases. Comparable as a Chinese biotech with similar HKEX-listed structure and R&D-driven innovation model.

TypeBroad incumbent
Description

Roche is Ascletis's strategic partner for Pegasys distribution in China and the originator of danoprevir (ASC08/Ganovo). Comparable as a broader pharma incumbent with established hepatitis franchise that overlaps with Ascletis's HCV commercial products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries12 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ascletis

Biopharmaceutical Therapeuticsascletis.com

Ascletis Pharma Inc. is a Hong Kong-listed biotechnology company (1672.HK) developing and commercializing differentiated small-molecule and peptide therapeutics — anchored by obesity lead ASC30 — using proprietary AI-assisted discovery, ultra-long-acting depot, and oral peptide delivery platforms, with legacy hepatitis products distributed across China.

What Ascletis does

Ascletis Pharma Inc. is a fully integrated, publicly traded (HKEX: 1672.HK) biotechnology company headquartered in Hangzhou, China, founded in 2013 by Dr. Jinzi Jason Wu. The company develops and commercializes small-molecule and peptide therapeutics with its primary current focus on metabolic diseases — particularly obesity — while retaining a legacy footprint in viral hepatitis (HCV/HBV). The technology base rests on three proprietary platforms: Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), the Ultra-Long-Acting Platform (ULAP) for subcutaneous depot formulations, and Peptide Oral Transport ENhancement Technology (POTENT), which the company claims delivers 3–5% oral bioavailability for peptides versus sub-1% with conventional SNAC formulations. Its lead clinical asset is ASC30, a small-molecule GLP-1R agonist designed for once-daily oral or once-monthly-to-quarterly subcutaneous dosing, supported by a portfolio of differentiated obesity candidates (ASC35 dual GLP-1R/GIPR, ASC36 amylin, ASC37 triple GLP-1R/GIPR/GCGR, ASC39 oral amylin, and an ASC30/ASC39 FDC).

The company's commercial revenue comes from a narrow hepatitis product set: Ganovo (Danoprevir), the first domestically developed DAA in China; Ravidasvir (ASC16); and exclusive mainland China sales/marketing rights for Roche's Pegasys for HBV/HCV, distributed via a strategic partnership with CR Pharmaceutical Commercial Group covering all 31 Chinese provinces. Pricing is mediated through provincial medical insurance reimbursement programs (Tianjin, Chengdu, Shaoxing, Zhejiang). Reported revenue is small (H1 prior-year revenue of approximately CNY 104M more than doubled year-over-year) and the company is unprofitable with annual losses of approximately CNY 359.88M, so equity value is driven primarily by pipeline optionality rather than current product cash flow. Additional late-stage assets include denifanstat (ASC40), a first-in-class oral FASN inhibitor for moderate-to-severe acne with NDA accepted by China's NMPA, and ASC22 (Envafolimab) for HBV functional cure.

Ascletis firmographics

Firmographics
Name
Ascletis
Legal name
Ascletis Pharma Inc.
Website
https://ascletis.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Ascletis Pharma Inc. is a Hong Kong-listed biotechnology company (1672.HK) developing and commercializing differentiated small-molecule and peptide therapeutics — anchored by obesity lead ASC30 — using proprietary AI-assisted discovery, ultra-long-acting depot, and oral peptide delivery platforms, with legacy hepatitis products distributed across China.
Ownership category
akta.pro rank

Ascletis industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Metabolic disease therapeutics
  • GLP-1 receptor agonists
  • Antiviral hepatitis drugs
  • Small molecule drug discovery
  • Peptide therapeutics platform

Where Ascletis is headquartered

Location

Headquarters

HQ city
Hangzhou
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Ascletis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Ganovo (Danoprevir) Sales: Commercial sales of Ganovo, the first domestically developed DAA for hepatitis C in China, with reimbursement access through multiple provincial medical insurance programs (Tianjin, Chengdu, Shaoxing, Zhejiang).
  2. Pegasys Distribution Partnership with Roche: Ascletis holds exclusive sales and marketing promotion rights for Pegasys (peginterferon alfa-2a) in mainland China for HBV and HCV, leveraging Roche's established brand and Ascletis's hepatitis focus.
  3. Denifanstat (ASC40) - Acne: First-in-class oral FASN inhibitor for moderate-to-severe acne vulgaris. NDA accepted by China's NMPA. Awaiting commercial launch.
  4. Licensing Royalties and Milestone Payments - Sagimet Partnership: Ascletis holds exclusive license to develop and commercialize Sagimet's FASN inhibitor denifanstat/ASC40 in Greater China, with milestone payments and tiered royalties from mid-teens to ~20% on net sales.
  5. Pipeline Drug Development - Clinical Milestones: Pre-revenue clinical-stage biopharma with multiple pipeline candidates (ASC30, ASC35, ASC36, ASC37, ASC39) advancing through clinical trials. Revenue generation contingent on successful clinical and regulatory outcomes.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Ascletis product offering

Product offering

Core offering

Ascletis is a fully integrated biotechnology company that discovers, develops, and commercializes therapeutics for metabolic diseases (primarily obesity and diabetes), viral hepatitis, NASH, and acne. The company uses three proprietary platforms—AI-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT)—to develop small molecule and peptide drug candidates such as ASC30 (lead GLP-1R agonist), ASC35, ASC36, ASC37, ASC39, Ganovo (HCV DAA), Ravidasvir, Pegasys, and denifanstat.

Product overview

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing and commercializing therapeutics for metabolic diseases. The company has developed multiple drug candidates in-house using its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). The portfolio includes ASC30 as the lead program (small molecule GLP-1R agonist with oral daily and subcutaneous monthly/quarterly dosing), supported by peptide agonists ASC35, ASC36, ASC37, and fixed-dose combinations. Commercial products include Ganovo and Ravidasvir for hepatitis C, Pegasys for HBV/HCV partnered with Roche, and denifanstat (ASC40) approaching launch for acne.

Differentiator

Problem solved

Functional benefit

Brands

  • Ganovo: First direct-acting anti-viral agent for hepatitis C developed domestically in China (Danoprevir)
  • ASC30
  • ASC36
  • ASC35
  • ASC37
  • ASC39
  • ASC40 (Denifanstat)
  • Pegasys

Products and services

  • ASC30
  • ASC35
  • ASC36
  • ASC37
  • ASC39
  • ASC30_39 FDC
  • Denifanstat (ASC40)
  • Ganovo (Danoprevir/ASC08)
  • Ravidasvir (ASC16)
  • Pegasys (Peginterferon alfa-2a)
  • ASC22 (Envafolimab)
  • ASC47
  • ASC50

Quantifiable outcome

  • ASC30 subcutaneous depot: 7.5% placebo-adjusted mean weight loss at Week 16 in 65 obese participants after 3 monthly doses (Phase II)
  • +8 more outcomes

Companies that use Ascletis

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Ascletis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Ascletis partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Roche (via Shanghai Roche Pharmaceuticals Ltd.)coreStrategic or Co-development PartnerIn November 2018, Ascletis and Roche entered an exclusive partnership granting Ascletis sales and marketing promotion rights for Pegasys (peginterferon alfa-2a) in mainland China for hepatitis B and C. Roche maintains manufacturing and supply. This builds on Ascletis' prior successful Ganovo partnership with Roche (which licensed danoprevir/ASC08 to Ascletis in 2013).
  • Suzhou Alphamab Co., Ltd.coreStrategic or Co-development PartnerIn January 2019, Ascletis entered an exclusive licensing and strategic collaboration with Alphamab for anti-PD-L1 KN035 (ASC22) to treat hepatitis B and other viral diseases in Greater China. Alphamab manufactures ASC22 for clinical trials and commercialization. In November 2021, the partnership was expanded into a worldwide license agreement.
  • Sagimet Biosciences (formerly 3-V Biosciences, Inc.)coreStrategic or Co-development PartnerIn February 2019, Ascletis and Sagimet entered an exclusive license agreement for FASN inhibitor TVB-2640 (denifanstat, ASC40) in Greater China. Ascletis led the $18M Series E financing and contributed to a further $7M tranche. Sagimet is developing denifanstat for NASH, acne, and other indications globally. Ascletis' NDA for denifanstat for acne has been accepted by China's NMPA. Sagimet is planning US Phase 3 acne trial in H2 2026.
  • CR Pharmaceutical Commercial Group Co., Ltd. (China Resources)coreChannel Partner/ Reseller/ DistributorIn June 2018, Ascletis and CR Pharmaceutical Commercial Group (a subsidiary of China Resources Pharmaceutical Group Limited, HK: 3320) signed a strategic cooperation agreement for distribution networks and end-user services for Ganovo. CR Pharma is China's second-largest pharmaceutical distributor, directly serving hospitals and medical institutions across all 31 provinces.
  • Medivir ABminorOEM/ Whitelabel/ Licensing PartnerIn August 2017, Ascletis licensed exclusive rights from Medivir to develop, manufacture and commercialize MIV-802 (ASC21), a nucleotide polymerase inhibitor for hepatitis C, in Greater China. Medivir received upfront and milestone payments plus tiered royalties.

Scale indicators9 records

Recent moves9 records

Expansion highlights7 records

Ascletis competitors and assessment

Company assessment

Direct peers

  • Innovent Biologics: Innovent Biologics is a leading Chinese biopharmaceutical company listed on HKEX with a focus on innovative medicines for oncology, metabolic diseases, and autoimmune conditions. Comparable as a Hong Kong-listed Chinese biotech with similar scale, R&D intensity, and pipeline breadth including metabolic disease programs (e.g., mazdutide).
  • Hansoh Pharmaceutical: Hansoh Pharmaceutical is one of China's largest innovative drug developers, listed on HKEX, with established presence in oncology, metabolic, and CNS therapeutic areas. Comparable as a Chinese pharmaceutical innovator with similar R&D-driven business model and HKEX listing.
  • Sagimet Biosciences: Sagimet Biosciences (NASDAQ: SGMT) is the originator and global developer of denifanstat (ASC40), the FASN inhibitor licensed to Ascletis for Greater China. Directly comparable as a co-developer of Ascletis's near-term commercial asset and as a metabolic disease-focused clinical-stage biotech.
  • Akeso Inc. Akeso Inc. is a Hong Kong-listed Chinese biotech developing novel bispecific antibodies and other biologics for cancer and autoimmune diseases. Comparable as a Chinese biotech with similar HKEX-listed structure and R&D-driven innovation model.

Broad incumbents

  • Eli Lilly: Eli Lilly is the global leader in the GLP-1 obesity market with Mounjaro (tirzepatide) and Zepbound. Ascletis directly references Eli Lilly's orforglipron as a Phase II comparator for ASC30, making it the most clinically relevant incumbent in Ascletis's core competitive set.
  • Novo Nordisk: Novo Nordisk is the dominant incumbent in diabetes and obesity with Ozempic/Wegovy (semaglutide), including the oral semaglutide formulation. Ascletis's ASC30 oral GLP-1 program directly competes for the same prescriber and patient pool.
  • Roche: Roche is Ascletis's strategic partner for Pegasys distribution in China and the originator of danoprevir (ASC08/Ganovo). Comparable as a broader pharma incumbent with established hepatitis franchise that overlaps with Ascletis's HCV commercial products.

Emerging players

  • Structure Therapeutics: Structure Therapeutics is a clinical-stage biotech developing oral small molecule GLP-1R agonists (GSBR-1290) for obesity. Directly comparable as a peer company pursuing oral small molecule GLP-1 with similar mechanism to ASC30, but focused exclusively on that asset.
  • Viking Therapeutics: Viking Therapeutics is a US clinical-stage biotech developing VK2735 (dual GLP-1/GIP agonist) and oral formulation programs. Directly comparable to Ascletis's ASC35/ASC37 dual and triple agonists in the obesity space, with similar mechanism of action.
  • Terns Pharmaceuticals: Terns Pharmaceuticals is a US-listed clinical-stage biotech developing oral GLP-1R agonist (TERN-601) and other metabolic disease assets. Comparable as a peer pursuing oral small molecule GLP-1 with similar mechanism to ASC30.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Ascletis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ascletis leadership team

Management profile

Number of profiles

Profiles6 records

Ascletis subsidiaries and ownership

Company hierarchy

Subsidiaries12 records

Ascletis funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ascletis M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascletis

What does Ascletis do?

Ascletis is a fully integrated biotechnology company that discovers, develops, and commercializes therapeutics for metabolic diseases (primarily obesity and diabetes), viral hepatitis, NASH, and acne. The company uses three proprietary platforms—AI-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT)—to develop small molecule and peptide drug candidates such as ASC30 (lead GLP-1R agonist), ASC35, ASC36, ASC37, ASC39, Ganovo (HCV DAA), Ravidasvir, Pegasys, and denifanstat.

Is Ascletis a public or private company?

Ascletis is a public company. It is classified as public and is currently operating.

When was Ascletis founded?

Ascletis was founded in 2013. It employs 11 to 50 people.

Where is Ascletis based?

Ascletis is headquartered in Hangzhou, China, in the Asia region.

How does Ascletis make money?

Five revenue lines are on record. Ganovo (Danoprevir) Sales are the primary driver. The others are pegasys Distribution Partnership with Roche, denifanstat (ASC40) - Acne, licensing Royalties and Milestone Payments - Sagimet Partnership and pipeline Drug Development - Clinical Milestones.

Who are Ascletis's main competitors?

Direct peers on record are Innovent Biologics, Hansoh Pharmaceutical, Sagimet Biosciences and Akeso Inc.. Broad incumbents are Eli Lilly, Novo Nordisk and Roche. Emerging players are Structure Therapeutics, Viking Therapeutics and Terns Pharmaceuticals.

Does Ascletis have an API?

No public API is recorded for Ascletis.

What industry is Ascletis in?

Ascletis's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAscletis Pharma Inc. Submits U.S. IND for Once-Weekly Oral Obesity DrugAscletis Pharma submitted a U.S. FDA IND for ASC36_37o FDC, a once-weekly oral obesity drug. In obese rat studies, the combination showed about 69% greater body weight reduction than ASC37 and 192% greater than ASC36. The filing advances the candidate toward clinical testing, with FDA clearance and trial initiation still ahead.TradingViewAscletis Pharma Inc. Reports Preclinical Weight-Loss Results for Two CandidatesAscletis Pharma reported preclinical weight-loss results for two candidates: ASC30_48 FDC reduced monkey weight 10.5% by Day 9 versus 6.9% with ASC30 alone, and ASC37 reduced DIO mouse weight up to 41.5% by Day 12. ASC37's half-life was 372 hours versus 57.8 hours for retatrutide, supporting less-frequent dosing. The company's lead ASC30 program is in two global Phase III obesity studies.FierceBiotechAscletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trialAscletis' ASC30 oral GLP-1 drug candidate met its primary and secondary endpoints in a phase 2 diabetes trial, with HbA1c falling 1.6-1.7% over 12 weeks. Weight loss was 3.8-4.4% placebo-adjusted, lower than Lilly's Foundayo. The company plans phase 3 trials in overweight and obesity, potentially filing for FDA approval by end of 2028.TradingViewAscletis Pharma Inc. Oral GLP-1 Cuts HbA1c 1.7% Vs Placebo at 12 WeeksAscletis Pharma reported that its oral GLP-1 ASC30 cut HbA1c by 1.6-1.7% versus placebo at 12 weeks and reduced body weight by 3.8-4.4% at 13 weeks in a 100-patient U.S. Phase II T2D study. The drug showed favorable GI tolerability and no hepatic safety signal, with an obesity Phase III trial enrolling and data expected in Q3 2028.TradingViewAscletis Pharma Inc. Files FDA IND for Oral Amylin Agonist ASC39Ascletis Pharma submitted an FDA IND for ASC39, an oral amylin receptor agonist for obesity, and expects to start a Phase I trial in Q4 2026. The drug showed 6.6% weight loss in diabetic obese rats over six days, and the company plans combo plans with oral GLP-1 ASC30.The future of tradingAscletis Pharma Files FDA Application to Test Obesity Drug ASC39Ascletis Pharma submitted an investigational new drug application to the FDA for ASC39, an oral selective amylin receptor agonist for obesity. A Phase I trial is expected to begin in the fourth quarter of 2026.TradingViewAscletis Pharma Inc. Partner Doses First U.S. Phase III Patient for Acne DrugAscletis Pharma's partner Sagimet dosed the first patient in AURORA, a U.S. Phase III trial of denifanstat for moderate to severe acne. The trial enrolls about 800 patients, including ~450 adolescents, and supports a potential U.S. NDA filing.MoomooHong Kong Stocks Move | Ascletis Pharma-B (01672) rises nearly 9% intraday; once-weekly oral peptide pipeline for obesity treatment yields positive preclinical dataAscletis Pharma reported positive preclinical data for its once-weekly oral peptide pipeline for obesity treatment, targeting four validated pathways. ASC36o, an oral amylin receptor agonist, is the fastest-advancing candidate, currently in a Phase I trial in the U.S. with a seven-day half-life and 6-8% oral bioavailability.TradingViewAscletis Pharma Inc. Reports Positive Preclinical Data for Once-Weekly Oral PeptidesAscletis Pharma reported positive preclinical data for its once-weekly oral peptide ASC36o, showing ~7–8.8 day half-lives and ≥6% oral bioavailability in non-human primates. A U.S. Phase I study has started, with topline PK data expected by end-2026.PR Newswire APACAscletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026Ascletis presented preclinical data for ASC36_35FDC at EASD 2026, showing greater weight loss than comparator co-formulations in a DIO rat model. The combination reduced body weight by 24.8% on Day 14, versus 12.5% and 16.8% for eloralintide/tirzepatide and MET-233i/tirzepatide, respectively. The data also demonstrated excellent formulation stability and ultra-long pharmacokinetics supporting once-monthly to once-quarterly dosing.